Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPROVEMENT-2: Vemurafenib and Cetuximab with FOLFIRI in BRAF V600E Colorectal Cancer
NCT06603376Phase 2Recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Sep 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of vemurafenib, KL-140 in colorectal carcinoma (CRC), sponsored by Shanghai Changzheng Hospital. Started Sep 2024; status: recruiting.
02
Drugs
vemurafenibKL-140
03
Conditions
colorectal carcinoma (CRC)
Beyond the preview
Go deeper on NCT06603376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06603376.